Igene Biotechnology, Inc.
IGNE · OTC
9/30/2010 | 6/30/2010 | 3/31/2010 | 12/31/2009 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.31 | -0.10 | -0.08 | 0.03 |
| FCF Yield | -4.54% | -3.80% | -0.07% | -4.16% |
| EV / EBITDA | -393.36 | -159.40 | -210.25 | -104.42 |
| Quality | ||||
| ROIC | -40.22% | -43.24% | 0.00% | 0.00% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 850.27% |
| Cash Conversion Ratio | 1.13 | 0.36 | 0.02 | 1.73 |
| Growth | ||||
| Revenue 3-Year CAGR | -91.75% | -45.21% | -19.25% | 20.07% |
| Free Cash Flow Growth | -139.07% | -2,246.52% | 98.04% | 6.50% |
| Safety | ||||
| Net Debt / EBITDA | -122.34 | -71.40 | -53.87 | -27.35 |
| Interest Coverage | -61.12 | -280.09 | -66.24 | -7.94 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 43,464.04 |